A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
- Sponsor
- Genentech, Inc.
- Study ID
- NCT00251459
- Phase
- PHASE3
- Status
- Completed
Conditions
- Age-related Macular Degeneration
- Choroidal Neovascularization
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- rhuFab V2 (ranibizumab) — DRUG
Study Details
This is a Phase IIIb, single-masked, 1-year multicenter study of the safety and tolerability of intravitreally administered ranibizumab in subjects with active subfoveal CNV secondary to AMD.
Key Dates
- First listed
- Nov 10, 2005
- Start date
- Nov 30, 2005
- Status verified
- Mar 2014
- Completion
- Sep 30, 2007
Study Design
- Enrollment
- 5,000 participants
- Primary purpose
- TREATMENT
Primary Outcome Measure
Cohort 1: The primary safety outcome measure is the incidence of SAEs (ocular and non ocular) evaluated through Month 12.
Related Studies
- National Eye Institute Biorepository for Retinal DiseasesRecruiting · National Eye Institute (NEI) · Bethesda, Maryland
- High Resolution Retinal ImagingRecruiting · University of Pennsylvania · Philadelphia, Pennsylvania
- Stem Cell Ophthalmology Treatment Study IIRecruiting · MD Stem Cells · Westport, Connecticut
- A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular DegenerationPHASE1 · Recruiting · Astellas Institute for Regenerative Medicine · Los Angeles, California